<DOC>
	<DOCNO>NCT02680782</DOCNO>
	<brief_summary>This study evaluate safety , tolerability pharmacokinetics X4P-001 administer 200 mg twice daily compare 400 mg daily . This study also assess pharmacodynamic effect X4P-001 administer 200 mg twice daily compare 400 mg daily level circulate white blood cell ( total cell type ) .</brief_summary>
	<brief_title>A Study Comparing Once-Daily vs. Twice-Daily Dosing X4P-001 Healthy Volunteers</brief_title>
	<detailed_description>This study conduct 15 healthy volunteer clinical research unit locate Daytona Beach , Florida . Screening do within 35 day prior first dose study drug ( first Dosing Period ) . Each subject complete two 10-day Dosing Periods , one use daily dose twice daily dosing . The interval Dosing Periods 7 17 day . Patients randomly assign regimen administer first Dosing Period . Safety laboratory test perform screening , prior Dosing Period . End-of-Study ( EOS ) visit , final study event , perform 14 21 day last dose study drug .</detailed_description>
	<criteria>1 . Between 18 65 year age , inclusive . 2 . Have sign current approve informed consent form . 3 . For woman childbearing potential , ( ) agree use effective contraceptive method screen , study , least 4 week last dose study drug ; ( b ) negative pregnancy test ( serum urine ) screen Day 1 prior Dosing period . 4 . For men , agree ( ) use effective contraceptive method ( b ) abstain donate sperm , admission inresidence unit prior first Dosing Period , study , least 4 week last dose study drug . 5 . Be willing able comply protocol . 1 . Is employee Phase 1 unit immediate family member employee . 2 . Has BMI &lt; 18.0 &gt; 30.0 . 3 . Has history hypersensitivity allergy drug compound , food substance assess significant Investigator . 4 . Has history presence medical condition capable alter absorption , metabolism elimination drug ( history routine cholecystectomy permit ) . 5 . Has alcohol intake exceed 21 unit per week male 14 unit per week female , 1 unit = 12 oz ( 360 mL ) beer , 5 oz ( 150 mL ) wine , 1.5 oz ( 45 mL ) distil spirit . 6 . Has within past 12 month use illicit drug . 7 . Has within past 6 month smoker use tobacco nicotine replacement product . 8 . Is within 6 month postpartum termination pregnancy . 9 . Has within past 30 day 5 halflives , whichever longer , participate clinical trial involve investigational treatment . 10 . Has within past 30 day acute medical illness , include active infection . 11 . Has within past 30 day donate 500 mL blood . 12 . Has within past 30 day , schedule participate study , surgery require general anesthesia . 13 . Has within past 30 day , schedule participate study , immunization . 14 . Has within past 14 day nursing . 15 . Has within past 14 day donate plasma . 16 . Has within past 14 day use prescription counter medication , unless deem acceptable Investigator . 17 . Has positive urine serum test drug abuse cotinine . 18 . Has positive serologic laboratory test : Human immunodeficiency virus ( HIV1 2 ) Hepatitis C virus ( HCV ) Hepatitis B virus ( HBV ) 19 . Has confirm abnormal safety laboratory test represent CTCAE Grade 2 high . Subjects Grade 1 abnormality may enrol approval Investigator Sponsor . 20 . Has insufficient venous access permit schedule blood sample . 21 . Has medical personal condition finding , opinion Investigator , may potentially compromise safety compliance subject , may preclude subject 's successful completion clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Comparison</keyword>
	<keyword>Once-Daily</keyword>
	<keyword>Twice-Daily</keyword>
	<keyword>X4P-001</keyword>
</DOC>